Annual report pursuant to Section 13 and 15(d)

Acquisition (Details Narrative)

v3.19.1
Acquisition (Details Narrative) - USD ($)
12 Months Ended
Oct. 04, 2017
Oct. 04, 2017
Dec. 31, 2018
Dec. 31, 2017
Number of shares acquired in exchange for common stock 31,745,242   2,090,301  
Common stock shares issued     38,674,265 35,272,626
Common stock shares outstanding     38,674,265 35,272,626
Promet Therapeutics LLC [Member]        
Equity ownership percentage     84.00%  
Promet Therapeutics LLC [Member] | General and Administrative Expense [Member]        
Acquisition-related transaction costs     $ 58,763  
Parent Company [Member]        
Business acquisition exchange percentage   90.00%    
Number of shares acquired in exchange for common stock   31,745,242    
Business acquisition acquired value $ 1,017,342 $ 1,017,342    
Common stock shares issued     35,272,626  
Common stock shares outstanding     35,272,626  
Percentage of common stock holdings     6.00%  
Voting interest     90.00%